Cancer of the Larynx and Hypopharynx

Hematol Oncol Clin North Am. 2021 Oct;35(5):933-947. doi: 10.1016/j.hoc.2021.05.005. Epub 2021 Jul 14.

Abstract

The Radiation Therapy Oncology Group 91-11 trial and US Veterans Affairs trial revolutionized the way locally advanced laryngeal cancers are treated. Adjuvant therapies exist aimed toward laryngeal preservation using docetaxel, cisplatin, and fluorouracil. Cetuximab is a cornerstone of treatment due to the large role of epidermal growth factor receptor in laryngeal and hypopharyngeal carcinomas. In addition, the immune system is vital in the prevention of recurrence, and various immunomodulators against programmed cell death receptor 1 are being investigated. Multidisciplinary management of the patient with laryngeal and hypopharyngeal is key, as many vital functions are affected by this devastating disease.

Keywords: Hypopharynx; Laryngeal carcinoma; Larynx; Squamous cell carcinoma.

Publication types

  • Review

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Carcinoma, Squamous Cell* / drug therapy
  • Cisplatin / therapeutic use
  • Fluorouracil / therapeutic use
  • Humans
  • Hypopharyngeal Neoplasms* / drug therapy
  • Hypopharynx
  • Laryngeal Neoplasms* / drug therapy

Substances

  • Cisplatin
  • Fluorouracil